Fibronostics is now officially SOC 2 Type II compliant! This compliance reflects our deep commitment to keeping your data and the trust you place in us –> safe, secure, and always protected.

SOC 2, developed by the AICPA (American Institute of Certified Public Accountants), is a gold standard for how service organizations handle sensitive data. It covers five trust principles: security, availability, processing integrity, confidentiality, and privacy.

Why it matters:

 Your data is secure: We meet the highest industry standards.

 You can trust us: Whether you’re a provider, lab, or partner, your information is in safe hands.

 We’re audit-proven: Our systems, processes, and controls have been independently verified.

This compliance validates that Fibronostics not only meets industry-leading standards but also ensures that its customers, from health systems and payers to diagnostic labs, can trust the safety and integrity of their data throughout the care journey.

­Our solutions, including LIVERFASt, are transforming liver health diagnostics by offering a non-invasive, accurate, and scalable alternative to liver biopsy. As we grow globally, SOC 2 compliance is just one more way we ensure our technology is reliable, secure, and ready for the future.­

Thank you for being on this journey with us.

Fibronostics is excited to announce our participation in the MASH-TAG 2026 Conference, held from January 8-10, 2026, in beautiful Deer Valley/Park City, UT. This marks our first conference representation of the new year, and we are eagerly looking forward to engaging with the MASH community.

We are especially proud to share that our team has been accepted for a poster presentation titled: “Dynamics of Noninvasive tests (NITs, LIVERFASt (LFAST), FIB-4 and Vibration-controlled transient elastography (VCTE, Fibroscan), during monitoring therapy with TNR-beta agonist Resmetirom (RT) in patients with MASH- Update.”

This presentation will delve into the dynamics of noninvasive tests on Resmetirom in MASH patients, offering valuable insights into real-world monitoring and clinical decision-making.

If you are attending MASH-TAG 2026, we warmly invite you to connect with us! Please find us during the poster session to discuss these crucial dynamics and their implications for liver health. We are keen to share our findings and engage in thoughtful discussions with fellow researchers and clinicians.

We anticipate a productive and insightful conference experience at MASH-TAG 2026!

At Fibronostics, our mission is built on a foundation of precision and trust. We are proud to announce that we have completed our latest ISO 13485:2016 audit, reaffirming our full compliance with the international gold standard for Medical Device Quality Management Systems (QMS).

ISO 13485:2016 is more than just a certificate on the wall; it is a rigorous framework that governs every stage of our product lifecycle. From initial design controls to risk-based manufacturing processes, this certification ensures that our medical devices are consistently safe, effective, and aligned with global regulatory expectations.

In the rapidly evolving landscape of HealthTech, maintaining this standard reflects the relentless discipline of our team. This achievement underscores our dedication to:

• Patient Safety: Ensuring every diagnostic tool meets the highest safety benchmarks.
• Regulatory Rigor: Meeting the strict demands of clinicians and partners worldwide.
• Continuous Improvement: Using data-driven insights to refine our quality management.

This milestone belongs to our entire team, whose teamwork and “quality-first” mindset make our innovation possible. As we look ahead, we remain committed to pushing the boundaries of healthcare with integrity and excellence.

Fibronostics will be participating in the upcoming American Diabetes Association (ADA) 2026 Scientific Sessions, taking place from June 5–8, 2026, in New Orleans, Louisiana.

At ADA 2026, Fibronostics will present new clinical findings on LIVERFASt™ and its performance in identifying advanced fibrosis in patients with MASLD, including patients with type 2 diabetes (T2D).

The poster highlights how LIVERFASt™, in sequential combination with vibration-controlled transient elastography (VCTE), supports clearer identification of ≥F3 fibrosis compared with traditional assessment approaches such as FIB-4.

Fibronostics is pleased to announce that new data on LIVERFASt™, its non-invasive blood-based diagnostic test for liver disease, will be presented at the EASL Congress 2026, taking place in Barcelona, Spain from 27–30 May 2026.

Two abstracts have been accepted for poster presentation within the MASLD: Diagnostics and Non-Invasive Assessment session, highlighting continued advancements in the clinical evaluation of metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH).

The accepted abstracts will explore:

• The role of LIVERFASt in identifying patients at risk of advanced fibrosis within MASLD populations, including those with type 2 diabetes (T2D)
• The evolving role of non-invasive tests in monitoring disease dynamics in patients undergoing emerging therapies

These presentations reflect Fibronostics’ ongoing commitment to advancing accessible, non-invasive approaches to liver disease assessment, supporting earlier detection and more informed clinical decision-making.

Fibronostics is pleased to share that Dr. Mona Munteanu, Chief Scientific Officer at Fibronostics, will be presenting new data on LIVERFASt™ at Digestive Disease Week (DDW) 2026, taking place from May 2–5, 2026 in Chicago.

The presentation will be part of the session:
“Noninvasive Tools for MASLD/MASH: Real-World Performance, Pitfalls, and Clinical Integration.”